Myriad Genetics 8-K

Summary

2026 annual meeting and equity-plan approvals. Stockholders approved an additional 4,000,000 shares for the employee stock purchase plan and a new equity incentive plan. Directors were elected, the auditor was ratified, and executive compensation was approved.

Key Figures

• Employee stock purchase plan: share authorization increased by 4,000,000 shares.
• 2026 equity incentive plan: 8,463,567 shares initially available, comprising 6,400,000 new shares and 2,063,567 shares rolled over from the 2017 plan. The reserve can increase by shares from forfeited, expired or cancelled 2017 plan awards, up to a maximum of 8,659,575 shares; no future awards will be granted under the 2017 plan.